Aberrant B cell selection and activation in systemic lupus erythematosus

International Reviews of Immunology

Volumn 32, Issue 4, 2013, Pages 445-470

  Kil, Laurens P ^a   Hendriks, Rudi W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antibody secreting cells; B cell activation; B cell receptor signaling; B cell tolerance; B lymphocytes; Follicular helper T cells; Germinal centers; Systemic lupus erythematosus; Toll like receptors

Indexed keywords

ABATACEPT; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; B LYMPHOCYTE RECEPTOR; BELUMIMAB; RITUXIMAB; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL INTERACTION; CELL MATURATION; CELL SELECTION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 84880854544     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2013.786712     Document Type: Article

References (252)

1. Tsokos GC. Systemic lupus erythematosus. N Engl JMed 2011;365(22):2110- 2121.
2. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007;369(9561): 587-596. (Pubitemid 46241445)
3. Isenberg DA,Manson JJ, EhrensteinMR, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey's end. Rheumatology 2007;46(7):1052- 1056. (Pubitemid 47050602)
4. Arbuckle MR,McClain MT, Rubertone MV, et al.Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl JMed 2003;349(16):1526-1533. (Pubitemid 37255038)
5. Kramers C,HylkemaMN, van Bruggen MC, et al. Anti-nucleosome antibodies complexed to nucleosomal antigens showanti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 1994;94(2):568-577.
6. Grootscholten C, van Bruggen MC, van der Pijl JW, et al. Deposition of nucleosomal antigens (histones and DNA) in the epidermal basementmembrane in human lupus nephritis. Arthritis Rheum 2003;48(5):1355-1362. (Pubitemid 36554534)
7. Kalaaji M, Mortensen E, Jorgensen L, et al. Nephritogenic lupus antibodies recognize glomerular basementmembrane-associated chromatin fragments released from apoptotic intraglomerular cells. AmJ Pathol 2006;168(6):1779-1792. (Pubitemid 43825300)
8. Chan OT, Hannum LG, Haberman AM, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999;189(10): 1639-1648.
9. Jiang C, Zhao ML, Scearce RM, Diaz M. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis. Arthritis Rheum 2011;63(4):1086-1096.
10. Ehrenstein MR, Notley CA. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 2010;10(11):778-786.
11. Nanton MR, Way SS, Shlomchik MJ, McSorley SJ. Cutting Edge: B cells are essential for protective immunity against Salmonella independent of antibody secretion. J Immunol 2012;189(12):5503-5507.
12. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010;10(4):236-247.
13. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1(6):475-482.
14. Townsend SE, Goodnow CC. Abortive proliferation of rare T cells induced by direct or indirect antigen presentation by rare B cells in vivo. J ExpMed 1998;187(10):1611-1621. (Pubitemid 28235102)
15. Bekar KW, Owen T, Dunn R, et al. Prolonged effects of short-termanti-CD20Bcell depletion therapy inmurine systemic lupus erythematosus. Arthritis Rheum 2010;62(8):2443-2457.
16. Looney RJ, Anolik JH,Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50(8):2580-2589. (Pubitemid 39062719)
17. Merrill JT,Neuwelt CM,Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62(1):222-233.
18. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011;20(7):709-716.
19. Rovin BH, Furie R, Latinis K. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64(4):1215-1226.
20. Coca A, Sanz I.Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol 2012;24(5):451-456.
21. Ahuja A, Shupe J, Dunn R, et al. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007;179(5):3351-3361.
22. Haas KM, Watanabe R, Matsushita T, et al. Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol 2010;184(9):4789-4800.
23. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9767):721-731.
24. Merrill JT, Ginzler EM,Wallace DJ, et al. Long-termsafety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64(10):3364-3373.
25. Jung D, Giallourakis C,Mostoslavsky R, Alt FW.Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol 2006;24:541-570.
26. WardemannH, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003;301(5638):1374-1377. (Pubitemid 37075812)
27. von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010;11(1):14-20.
28. Nishimoto N, Kubagawa H, Ohno T, et al. Normal pre-B cells express a receptor complex of mu heavy chains and surrogate light-chain proteins. Proc Natl Acad Sci USA 1991;88(14):6284-6288. (Pubitemid 21914930)
29. Lassoued K, Nunez CA, Billips L, et al. Expression of surrogate light chain receptors is restricted to a late stage in pre-B cell differentiation. Cell 1993;73(1):73-86. (Pubitemid 23115450)
30. Kline GH, Hartwell L, Beck-Engeser GB. Pre-B cell receptor-mediated selection of pre-B cells synthesizing functionalmu heavy chains. J Immunol 1998;161(4):1608-1618. (Pubitemid 28387575)
31. Herzog S, Jumaa H. Self-recognition and clonal selection: autoreactivity drives the generation of B cells. Curr Opin Immunol 2012;24(2):166-172.
32. Ohnishi K, Melchers F. The nonimmunoglobulin portion of lambda5 mediates cell-autonomous pre-B cell receptor signaling. Nat Immunol 2003;4(9):849-856. (Pubitemid 37098655)
33. BradlH,Wittmann J,MiliusD, et al. Interaction ofmurine precursorBcell receptorwith stroma cells is controlled by the unique tail of lambda 5 and stroma cell-associated heparan sulfate. J Immunol 2003;171(5):2338-2348. (Pubitemid 37025540)
34. Gauthier L, Rossi B, Roux F, et al. Galectin-1 is a stromal cell ligand of the pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR triggering. Proc Natl Acad Sci USA 2002;99(20):13014-13019.
35. Kohler F, Hug E, Eschbach C, et al. Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells. Immunity 2008;29(6):912-921.
36. Ubelhart R, Bach MP, Eschbach C, et al. N-linked glycosylation selectively regulates autonomous precursor BCR function. Nat Immunol 2010;11(8):759-765.
37. Eschbach C, Bach MP, Fidler I, et al. Efficient generation of B lymphocytes by recognition of selfantigens. Eur J Immunol 2011;41(8):2397-2403.
38. Keenan RA, De Riva A, Corleis B, et al. Censoring of autoreactive B cell development by the pre-B cell receptor. Science 2008;321(5889):696-699.
39. Kitamura D, Kudo A, Schaal S, et al. A critical role of lambda 5 protein in B cell development. Cell 1992;69(5):823-831.
40. Minegishi Y, ConleyME.Negative selection at the pre-BCR checkpoint elicited by humanmu heavy chains with unusual CDR3 regions. Immunity 2001;14(5):631-641. (Pubitemid 32520873)
41. Meffre E, Davis E, Schiff C. Circulating human B cells that express surrogate light chains and edited receptors. Nat Immunol 2000;1(3):207-213.
42. Meffre E, Chiorazzi M, Nussenzweig MC. Circulating human B cells that express surrogate light chains display a unique antibody repertoire. J Immunol 2001;167(4):2151-2156. (Pubitemid 32747524)
43. Meffre E, Schaefer A, Wardemann H, et al. Surrogate light chain expressing human peripheral B cells produce self-reactive antibodies. J ExpMed 2004;199(1):145-150. (Pubitemid 38076487)
44. Geier JK, Schlissel MS. Pre-BCR signals and the control of Ig gene rearrangements. Semin Immunol 2006;18(1):31-39. (Pubitemid 43238334)
45. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989;337(6207):562-566. (Pubitemid 19045542)
46. Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bonemarrow B cells. J ExpMed 1993;177(4):1009-1020. (Pubitemid 23097390)
47. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J ExpMed 1993;177(4):999-1008. (Pubitemid 23097389)
48. Vela JL, Ait-Azzouzene D,Duong BH, et al. Rearrangement ofmouse immunoglobulin kappa deleting element recombining sequence promotes immune tolerance and lambda B cell production. Immunity 2008;28(2):161-170.
49. Retter MW, Nemazee D. Receptor editing occurs frequently during normal B cell development. J ExpMed 1998;188(7):1231-1238. (Pubitemid 28478011)
50. Casellas R, Shih TA, Kleinewietfeld M. Contribution of receptor editing to the antibody repertoire. Science 2001;291(5508):1541-1544. (Pubitemid 32179219)
51. Halverson R, Torres RM, Pelanda R. Receptor editing is the main mechanism of B cell tolerance towardmembrane antigens. Nat Immunol 2004;5(6):645-650. (Pubitemid 38811890)
52. Lamoureux JL, Watson LC, Cherrier M, et al. Reduced receptor editing in lupus-prone MRL/lpr mice. J ExpMed 2007;204(12):2853-2864. (Pubitemid 350179555)
53. Panigrahi AK,Goodman NG, Eisenberg RA, et al. RS rearrangement frequency as amarker of receptor editing in lupus and type 1 diabetes. J ExpMed 2008;205(13):2985-2994.
54. Li Y, Li H, Weigert M. Autoreactive B cells in the marginal zone that express dual receptors. J Exp Med 2002;195(2):181-188. (Pubitemid 34461262)
55. Gerdes T, Wabl M. Autoreactivity and allelic inclusion in a B cell nuclear transfer mouse. Nat Immunol 2004;5(12): 1282-1287. (Pubitemid 41057744)
56. Liu S, Velez MG, Humann J, et al. Receptor editing can lead to allelic inclusion and development of B cells that retain antibodies reacting with high avidity autoantigens. J Immunol 2005;175(8):5067-5076. (Pubitemid 41456390)
57. Casellas R, Zhang Q, ZhengNY, et al. Igkappa allelic inclusion is a consequence of receptor editing. J ExpMed 2007;204(1):153-160. (Pubitemid 46148765)
58. PauzaME,Rehmann JA, LeBien TW.Unusual patterns ofimmunoglobulin gene rearrangement and expression during human B cell ontogeny: human B cells can simultaneously express cell surface kappa and lambda light chains. J ExpMed 1993;178(1):139-149. (Pubitemid 23173250)
59. Giachino C, Padovan E, Lanzavecchia A. kappa+lambda+ dual receptor B cells are present in the human peripheral repertoire. J ExpMed 1995;181(3):1245-1250.
60. Fournier EM, Velez MG, Leahy K, et al. Dual-reactive B cells are autoreactive and highly enriched in the plasmablast and memory B cell subsets of autoimmune mice. J Exp Med 2012;209(10):1797-1812.
61. Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol 2005;6(11):1160-1167. (Pubitemid 41541794)
62. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and geneticmechanisms of self tolerance and autoimmunity. Nature 2005;435(7042):590-597. (Pubitemid 40825498)
63. Shlomchik MJ. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008;28(1):18-28.
64. Cambier JC, Gauld SB,Merrell KT, Vilen BJ. B-cell anergy: fromtransgenicmodels to naturally occurring anergic B cells? Nat Rev Immunol 2007;7(8):633-643. (Pubitemid 47123549)
65. Erikson J, Radic MZ, Camper SA, et al. Expression of anti-DNA immunoglobulin transgenes in nonautoimmune mice. Nature 1991;349(6307):331-334. (Pubitemid 21912076)
66. Nguyen KA, Mandik L, Bui A, et al. Characterization of anti-single-stranded DNA B cells in a nonautoimmune background. J Immunol 1997;159(6):2633-2644. (Pubitemid 127681281)
67. Roark JH, Bui A, Nguyen KA, et al. Persistence of functionally compromised anti-double-stranded DNA B cells in the periphery of non-autoimmunemice. Int Immunol 1997;9(11):1615-1626. (Pubitemid 27494125)
68. Mandik-Nayak L, Seo SJ, Sokol C, et al. MRL-lpr/lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti-double-stranded DNA B cells. J Exp Med 1999;189(11):1799-1814. (Pubitemid 29272697)
69. Merrell KT, Benschop RJ, Gauld SB, Aviszus K. Identification of anergic B cells within a wild-type repertoire. Immunity 2006;25(6):953-962. (Pubitemid 44894955)
70. Culton DA, O'Conner BP, Conway KL, et al. Early preplasma cells define a tolerance checkpoint for autoreactive B cells. J Immunol 2006;176(2):790-802. (Pubitemid 43099675)
71. Zikherman J, Parameswaran R, Weiss A. Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature 2012;489(7414):160-164.
72. Healy JI, Dolmetsch RE, Timmerman LA, et al. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity 1997;6(4):419-428. (Pubitemid 27208197)
73. Dolmetsch RE, Lewis RS, Goodnow CC, Healy JI. Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature 1997;386(6627):855-858. (Pubitemid 27181262)
74. Browne CD, Del Nagro CJ, Cato MH, et al. Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy. Immunity 2009;31(5):749-760.
75. O'Neill SK, Getahun A, Gauld SB, et al. Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy. Immunity 2011;35(5):746-756.
76. Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J ExpMed 2005;201(5):703-711. (Pubitemid 40395116)
77. Yurasov S, Tiller T, TsuijiM, et al. Persistent expression of autoantibodies in SLE patients in remission. J ExpMed 2006;203(10):2255-2261. (Pubitemid 44498360)
78. Sims GP, Ettinger R, Shirota Y, et al. Identification and characterization of circulating human transitional B cells. Blood 2005;105(11):4390-4398. (Pubitemid 40720786)
79. Dorner T, JacobiAM,Lee J, Lipsky PE.Abnormalities ofBcell subsets inpatientswith systemic lupus erythematosus. J ImmunolMethods 2011;363(2):187-197.
80. Vossenkamper A, Lutalo PM, Spencer J. Translational mini-review series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjogren's syndrome: clinical implications and effects of B cell-targeted therapies. Clin Exp Immunol 2012;167(1):7-14.
81. Odendahl M, Jacobi A,Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165(10):5970-5979.
82. Harada Y, Kawano MM, Huang N, et al. Identification of early plasma cells in peripheral blood and their clinical significance. Br J Haematol 1996;92(1):184-191. (Pubitemid 26018787)
83. Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48(5):1332-1342. (Pubitemid 36554532)
84. Tsuiji M, Yurasov S, Velinzon K, et al. A checkpoint for autoreactivity in human IgM+memory B cell development. J ExpMed 2006;203(2):393-400. (Pubitemid 43290848)
85. Mietzner B, Tsuiji M, Scheid J, et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci USA 2008;105(28):9727-9732. (Pubitemid 352031368)
86. Fecteau JF, Cote G, Neron S. A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somaticmutation. J Immunol 2006;177(6):3728-3736. (Pubitemid 44359905)
87. Wei C, Anolik J, Cappione A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007;178(10):6624-6633. (Pubitemid 46717447)
88. Jacobi AM, Reiter K,Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008;58(6):1762-1773. (Pubitemid 351847530)
89. Dorner T, Giesecke C, Lipsky PE. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 2011;13(5): 243.
90. Casola S, Otipoby KL, Alimzhanov M, et al. B cell receptor signal strength determines B cell fate.Nat Immunol 2004;5(3): 317-327. (Pubitemid 38332129)
91. Maas A, Dingjan GM, Grosveld F, Hendriks RW. Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinasemutant under the control of the CD19 promoter region. J Immunol 1999;162(11):6526-6533. (Pubitemid 29309375)
92. Dingjan GM, Maas A, Nawijn MC, et al. Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase. EMBO J 1998;17(18):5309-5320. (Pubitemid 28427046)
93. Kersseboom R, Kil L, Flierman R, et al. Constitutive activation of Bruton's tyrosine kinase induces the formation of autoreactive IgMplasma cells. Eur J Immunol 2010;40(9):2643-2654.
94. Sato S,Hasegawa M, Fujimoto M, et al.Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000;165(11): 6635-6643.
95. Paus D, Phan TG, Chan TD, et al. Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation. J Exp Med 2006;203(4):1081-1091.
96. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficientmice results from strain-specific epistasis. Immunity 2000;13(2):277-285.
97. Jellusova J, Wellmann U, Amann K, et al. CD22 x Siglec-G double-deficient mice have massively increased B1 cell numbers and develop systemic autoimmunity. JImmunol 2010;184(7):3618-3627.
98. Hibbs ML, Tarlinton DM, Armes J, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995;83(2):301-311.
99. Tsui HW, Siminovitch KA, de Souza L, Tsui FW.Motheaten and viablemotheaten mice havemutations in the haematopoietic cell phosphatase gene. Nat Genet 1993;4(2):124-129. (Pubitemid 23179093)
100. Pao LI, Lam KP, Henderson JM, et al. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 2007;27(1): 35-48. (Pubitemid 47089020)
101. Kil LP, de Bruijn MJ, van Nimwegen M, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 2012;119(16):3744-3756.
102. Bretscher P, CohnM. A theory of self-nonself discrimination. Science 1970;169(3950):1042-1049.
103. Rifkin IR, Leadbetter EA, Busconi L, et al. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005;204:27-42. (Pubitemid 40460491)
104. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgMand Toll-like receptors. Nature 2002;416(6881):603-607. (Pubitemid 34406754)
105. Sweet RA, Cullen JL, Shlomchik MJ. Rheumatoid factor B cell memory leads to rapid, switched antibody-forming cell responses. J Immunol 2013;190(5):1974-1981.
106. Viglianti GA, Lau CM,Hanley TM, et al. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003;19(6):837-847. (Pubitemid 37542304)
107. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J ExpMed 2005;202(9):1171-1177. (Pubitemid 41586947)
108. Shlomchik MJ. Activating systemic autoimmunity: B's, T's, and tolls. Curr Opin Immunol 2009;21(6):626-633.
109. Christensen SR, Kashgarian M, Alexopoulou L, et al. Toll-like receptor 9 controls anti-DNA autoantibody production inmurine lupus. J ExpMed 2005;202(2):321-331. (Pubitemid 41043827)
110. Christensen SR, Shupe J, Nickerson K, et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006;25(3):417-428. (Pubitemid 44354217)
111. Ehlers M, Fukuyama H,McGaha TL, et al. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J ExpMed 2006;203(3):553-561.
112. Lartigue A, Courville P, Auquit I, et al. Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lprmutation-inducedmurine lupus. J Immunol 2006;177(2):1349-1354. (Pubitemid 44036642)
113. Pisitkun P, Deane JA, Difilippantonio MJ, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006;312(5780):1669-1672. (Pubitemid 43902669)
114. Subramanian S, Tus K, Li QZ, et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 2006;103(26):9970-9975. (Pubitemid 43993607)
115. Deane JA, Pisitkun P, Barrett RS, et al. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007;27(5):801-810. (Pubitemid 350102256)
116. Herlands RA, Christensen SR, Sweet RA, et al. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 2008;29(2):249-260.
117. Yu P, Wellmann U, Kunder S, et al. Toll-like receptor 9-independent aggravation of glomerulonephritis in a novelmodel of SLE. Int Immunol 2006;18(8):1211-1219. (Pubitemid 44349296)
118. Nickerson KM, Christensen SR, Cullen JL, Meng W. TLR9 promotes tolerance by restricting survival of anergic anti-DNA B cells, yet is also required for their activation. J Immunol 2013;190(4):1447-1456.
119. Kool M, van Loo G,WaelputW.The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 2011;35(1):82-96.
120. Lee YH, Lee HS, Choi SJ, et al. Associations between TLR polymorphisms and systemic lupus erythematosus: a systematic review and meta-analysis. Clin Exp Rheumatol 2012;30(2):262-265.
121. Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008;40(9):1062-1064.
122. Jacob CO, Zhu J, Armstrong DL, et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 2009;106(15):6256-6261.
123. Gottipati S, Rao NL, Fung-Leung WP. IRAK1: a critical signaling mediator of innate immunity. Cellular signaling 2008;20(2):269-276.
124. Graham RR, Kozyrev SV, Baechler EC, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006;38(5):550-555.
125. Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 2010;6(12):683-692.
126. Takaoka A, Yanai H, Kondo S, et al. Integral role of IRF-5 in the gene induction programmeactivated by Toll-like receptors. Nature 2005;434(7030):243- 249. (Pubitemid 40388058)
127. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007;2(1):58-61.
128. Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102(5):553-563.
129. Stavnezer J. Complex regulation and function of activation-induced cytidine deaminase. Trends Immunol 2011;32(5):194-201.
130. Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol 2012;30:429-457.
131. ShlomchikMJ,Weisel F. Germinal center selection and the development ofmemory B and plasma cells. Immunol Rev 2012;247(1):52-63.
132. Shlomchik M, Mascelli M, Shan H. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somaticmutation. J ExpMed 1990;171(1):265-292.
133. Winkler TH, Fehr H, Kalden JR. Analysis of immunoglobulin variable region genes fromhuman IgG anti-DNA hybridomas. Eur J Immunol 1992;22(7):1719-1728.
134. Zhang J, Jacobi AM, Wang T, Diamond B. Pathogenic autoantibodies in systemic lupus erythematosus are derived from both self-reactive and non-self-reactive B cells. Mol Med 2008;14(11-12):675-681.
135. Jacobson BA, Panka DJ,Nguyen KA, et al. Anatomy of autoantibody production: dominant localization of antibody-producing cells to T cell zones in Fas-deficient mice. Immunity 1995;3(4):509-519.
136. William J, Euler C, Christensen S, Shlomchik MJ. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 2002;297(5589):2066-2070.
137. William J, Euler C, Leadbetter E, et al. Visualizing the onset and evolution of an autoantibody response in systemic autoimmunity. J Immunol 2005;174(11):6872-6878. (Pubitemid 40705651)
138. Vinuesa CG, Sanz I, Cook MC. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol 2009;9(12):845-857.
139. Luzina IG,Atamas SP, StorrerCE. Spontaneous formation of germinal centers in autoimmunemice. J Leukoc Biol 2001;70(4):578-584. (Pubitemid 32954768)
140. Cappione A, 3rd, Anolik JH, Pugh-Bernard A, et al.Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 2005;115(11):3205-3216. (Pubitemid 41567585)
141. Young CL, Adamson TC, 3rd, Vaughan JH, Fox RI. Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis. Arthritis Rheum 1984;27(1):32-39. (Pubitemid 14176534)
142. Stott DI, Hiepe F, Hummel M, et al. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest 1998;102(5):938-946. (Pubitemid 28419239)
143. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases.Nat Rev Immunol 2006;6(3):205-217. (Pubitemid 43290990)
144. VictoraGD, Schwickert TA, Fooksman DR, et al.Germinal center dynamics revealed bymultiphoton microscopy with a photoactivatable fluorescent reporter. Cell 2010;143(4):592-605.
145. Schwickert TA, Victora GD, Fooksman DR. A dynamic T cell-limited checkpoint regulates affinitydependent B cell entry into the germinal center. J ExpMed 2011;208(6):1243-1252.
146. Khalil AM, Cambier JC, Shlomchik MJ. B cell receptor signal transduction in the GC is shortcircuited by high phosphatase activity. Science 2012;336(6085):1178-1181.
147. Rathmell JC, Townsend SE, Xu JC, et al. Expansion or elimination of B cells in vivo: dual roles for CD40-and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996;87(2): 319-329. (Pubitemid 26359009)
148. Schram BR, Rothstein TL. NF-kappa B is required for surface Ig-induced Fas resistance in B cells. J Immunol 2003;170(6):3118-3124. (Pubitemid 36302187)
149. Zhang Y, Meyer-Hermann M, George LA, et al. Germinal center B cells govern their own fate via antibody feedback. J ExpMed 2013;210(3):457-464.
150. Renshaw BR, FanslowWC, 3rd, Armitage RJ. Humoral immune responses in CD40 ligand-deficient mice. J ExpMed 1994;180(5):1889-1900. (Pubitemid 24328578)
151. Han S, Hathcock K, Zheng B, et al. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J Immunol 1995;155(2):556-567.
152. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development ofmurine lupus nephritis. J Immunol 1995;154(3):1470-1480.
153. KoshyM, Berger D, CrowMK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98(3):826-837. (Pubitemid 26349188)
154. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97(9):2063-2073. (Pubitemid 26143961)
155. Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 1998;160(5):2158-2165. (Pubitemid 28119894)
156. Huang W, Sinha J, Newman J, et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002;46(6):1554-1562. (Pubitemid 34620202)
157. Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003;112(10):1506-1520. (Pubitemid 38056277)
158. Kalunian KC, Davis JC, Jr., Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulationwith anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46(12):3251-3258. (Pubitemid 35453534)
159. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48(3):719-727. (Pubitemid 36302008)
160. Goodnow CC.Multistep pathogenesis of autoimmune disease. Cell 2007;130(1):25-35. (Pubitemid 47031326)
161. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265(5176):1225-1227. (Pubitemid 24291979)
162. Mihara M, Tan I, Chuzhin Y, et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000;106(1):91-101. (Pubitemid 30437244)
163. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A . The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month,multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62(10): 3077-3087.
164. CroftM, SoT,Duan W, SorooshP.The significance ofOX40 andOX40L toT-cell biology andimmune disease. Immunol Rev 2009;229(1):173-191.
165. Stuber E, NeurathM, Calderhead D, et al. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 1995;2(5):507-521.
166. CunninghameGrahamDS,GrahamRR,MankuH, et al. Polymorphism at theTNFsuperfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat Genet 2008;40(1):83-89.
167. Crotty S, Kersh EN, Cannons J, et al. SAP is required for generating long-term humoral immunity. Nature 2003;421(6920):282-287. (Pubitemid 36139134)
168. Hron JD, Caplan L, Gerth AJ, et al. SH2D1A regulates T-dependent humoral autoimmunity. J Exp Med 2004;200(2):261-266. (Pubitemid 38982185)
169. Qi H, Cannons JL, Klauschen F, et al. SAP-controlled T-B cell interactions underlie germinal centre formation. Nature 2008;455(7214):764-769.
170. Qi H. From SAP-less T cells to helpless B cells and back: dynamic T-B cell interactions underlie germinal center development and function. Immunol Rev 2012;247(1):24-35.
171. Komori H, Furukawa H, Mori S, et al. A signal adaptor SLAM-associated protein regulates spontaneous autoimmunity and Fas-dependent lymphoproliferation in MRL-Faslpr lupus mice. J Immunol 2006;176(1):395-400. (Pubitemid 43023286)
172. Vinuesa CG, Cook MC, Angelucci C, et al. A RING-type ubiquitin ligase familymember required to repress follicular helper T cells and autoimmunity. Nature 2005;435(7041):452-458. (Pubitemid 40734237)
173. LintermanMA, Rigby RJ,Wong RK, et al. Follicular helper T cells are required for systemic autoimmunity. J ExpMed 2009;206(3): 561-576.
174. Nutt SL, Tarlinton DM.Germinal center B and follicular helper T cells: siblings, cousins or just good friends? Nat Immunol 2011;12(6):472-477.
175. Yoshinaga SK,Whoriskey JS,Khare SD, et al. T-cell co-stimulation through B7RP-1 and ICOS.Nature 1999;402(6763):827-832. (Pubitemid 129638129)
176. Akiba H, Takeda K, Kojima Y, et al. The role of ICOS in the CXCR5+ follicular B helper T cellmaintenance in vivo. J Immunol 2005;175(4):2340-2348. (Pubitemid 41113843)
177. Bossaller L, Burger J, Draeger R, et al. ICOS deficiency is associated with a severe reduction of CXCR5+CD4 germinal centerThcells. J Immunol 2006;177(7):4927-4932. (Pubitemid 44469829)
178. Hu YL,Metz DP, Chung J, B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J Immunol 2009;182(3):1421-1428.
179. Odegard JM,Marks BR, DiPlacido LD, et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J ExpMed 2008;205(12):2873-2886.
180. Hutloff A, Buchner K, Reiter K, et al. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 2004;50(10):3211-3220. (Pubitemid 39371998)
181. Bauquet AT, Jin H, Paterson AM, et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol 2009;10(2):167-175.
182. Vogelzang A,McGuire HM, Yu D, et al. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 2008;29(1):127-137.
183. Nurieva RI, Chung Y, Hwang D, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 2008;29(1):138-149.
184. Zotos D, Coquet JM, Zhang Y, et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsicmechanism. J ExpMed 2010;207(2):365-378.
185. Bubier JA, Sproule, Foreman TJ, et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci USA 2009;106(5): 1518-1523.
186. Rankin AL, Guay H, Herber D, et al. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J Immunol 2012;188(4): 1656-1667.
187. Herber D, Brown TP, Liang S, et al. IL-21 has a pathogenic role in a lupus-pronemouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007;178(6):3822-3830. (Pubitemid 46417651)
188. SawalhaAH,KaufmanKM,Kelly JA, et al.Genetic association of interleukin-21 polymorphismswith systemic lupus erythematosus. Ann Rheum Dis 2008;67(4):458-461. (Pubitemid 351498423)
189. Webb R, Merrill JT, Kelly JA, et al. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 2009;60(8):2402-2407.
190. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007;448(7152):484-487. (Pubitemid 47123515)
191. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8(9):967-974. (Pubitemid 47300011)
192. Yu D, Rao S, Tsai LM, et al.The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 2009;31(3):457-468.
193. Wu HY, Quintana FJ,Weiner HL. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25-LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells. J Immunol 2008;181(9):6038-6050.
194. Hsu HC, Yang P, Wang J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008;9(2):166-175.
195. Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009;10(7):778-785.
196. Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al. Lymphoproliferation disorder inmice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356(6367):314-317.
197. Takahashi T, TanakaM, Brannan CI, et al. Generalized lymphoproliferative disease inmice, caused by a pointmutation in the Fas ligand. Cell 1994;76(6):969-976. (Pubitemid 24106378)
198. Rieux-Laucat F. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268(5215): 1347-1349.
199. Fischer U, Huber J, Boelens WC, et al.The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 1995;82(3):475-483.
200. Drappa J, Vaishnaw AK, Sullivan KE, et al. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996;335(22):1643-1649. (Pubitemid 26392729)
201. Holzelova E, Vonarbourg C, Stolzenberg MC. Autoimmune lymphoproliferative syndrome with somatic Fasmutations. N Engl JMed 2004;351(14):1409-1418. (Pubitemid 39288167)
202. Jenks SA, Sanz I. Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev 2009;8(3):209-213.
203. Harley IT, Kaufman KM, Langefeld CD, et al. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet 2009;10(5):285-290.
204. Kozyrev SV, Abelson AK,Wojcik J, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 2008;40(2):211-216. (Pubitemid 351171404)
205. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8(1):34-47.
206. Brownlie RJ, Lawlor KE, Niederer HA, et al. Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J ExpMed 2008;205(4):883-895. (Pubitemid 351549885)
207. Rahman ZS, Niu H, Perry D, Wakeland E, et al. Expression of the autoimmune Fcgr2b NZW allele fails to be upregulated in germinal center B cells and is associated with increased IgG production. Genes Immun 2007;8(7):604-612. (Pubitemid 350011692)
208. Mackay M, Stanevsky A,Wang T, et al. Selective dysregulation of the FcgammaIIB receptor onmemory B cells in SLE. J ExpMed 2006;203(9):2157-2164. (Pubitemid 44352236)
209. Su K, Yang H, Li X, et al. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol 2007;178(5):3272-3280. (Pubitemid 46333211)
210. Lee YH, Ji JD, Song GG. Fcgamma receptor IIB and IIIB polymorphisms and susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Lupus 2009;18(8): 727-734.
211. Chen JY, Wang CM, Ma CC, et al. Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients. Arthritis Rheum 2006;54(12):3908-3917. (Pubitemid 44955894)
212. Kyogoku C, Dijstelbloem HM, Tsuchiya N, et al. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum 2002;46(5):1242-1254. (Pubitemid 34525832)
213. Niederer HA,ClatworthyMR, Willcocks LC, SmithKG. FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann N Y Acad Sci 2010;1183:69-88.
214. Groom J,Mackay F. B cells flying solo. Immunol Cell Biol 2008;86(1):40-46.
215. Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 2011;244(1):115-133.
216. Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293(5537):2108- 2111. (Pubitemid 32848062)
217. Hsu BL, Harless SM, Lindsley RC, et al. Cutting edge: BLyS enables survival of transitional andmature B cells through distinct mediators. J Immunol 2002;168(12):5993-5996. (Pubitemid 34620011)
218. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009;9(7):491-502.
219. Groom JR, Fletcher CA, Walters SN, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J ExpMed 2007;204(8):1959-1971. (Pubitemid 47236330)
220. Yu G, Boone T, Delaney J, et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000;1(3):252-256.
221. Mantchev GT, Cortesao CS, RebrovichM, et al. TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens. J Immunol 2007;179(4):2282-2288.
222. Day ES, Cachero TG, Qian F, et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 2005;44(6):1919-1931. (Pubitemid 40223621)
223. Marsters SA, Yan M, Pitti RM, et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Current biology: CB 2000;10(13):785-788. (Pubitemid 30466942)
224. Xu S, Lam KP. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001;21(12):4067-4074. (Pubitemid 32476467)
225. O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J ExpMed 2004;199(1):91-98.
226. Bergtold A, Desai DD, Gavhane A, Clynes R. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 2005;23(5):503-514. (Pubitemid 41587890)
227. Qi H, Egen JG, Huang AY, Germain RN. Extrafollicular activation of lymph node B cells by antigenbearing dendritic cells. Science 2006;312(5780):1672- 1676. (Pubitemid 43902670)
228. Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3(9):822-829.
229. Balazs M, Martin F, Zhou T, Kearney J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 2002;17(3):341-352. (Pubitemid 35279554)
230. Tezuka H, Abe Y, Iwata M, et al. Regulation of IgA production by naturally occurring TNF/iNOSproducing dendritic cells. Nature 2007;448(7156):929-933. (Pubitemid 47312771)
231. Craxton A, Magaletti D, Ryan EJ, Clark EA. Macrophage-and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003;101(11):4464-4471. (Pubitemid 36857815)
232. Puga I, Cols M, Barra CM, et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in themarginal zone of the spleen. Nat Immunol 2012;13(2):170-180.
233. Planelles L,Carvalho-PintoCE,Hardenberg G, et al.APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 2004;6(4):399-408. (Pubitemid 39361440)
234. Mackay F,Woodcock SA, Lawton P, et al.Mice transgenic for BAFF develop lymphocytic disorders along with autoimmunemanifestations. J ExpMed 1999;190(11):1697-1710. (Pubitemid 30002351)
235. Huang W, Moisini I, Bethunaickan R, et al. BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus. J Immunol 2011;187(12):6571-6580.
236. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303(5663):1532-1535. (Pubitemid 38314426)
237. Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol 2012;189(6): 2689-2695.
238. Baumann I, Kolowos W, Voll RE, et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002;46(1):191-201. (Pubitemid 34121664)
239. Gaipl US, Kuhn A, Sheriff A, et al. Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun 2006;9:173-187.
240. Knight JS, Kaplan MJ. Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis. Curr Opin Rheumatol 2012;24(5):441-450.
241. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci TranslMed 2011;3(73):73ra20.
242. Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011;3(73):73ra19.
243. Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011;187(1): 538-552.
244. Ronnblom L, ElorantaML.Theinterferon signature in autoimmune diseases. CurrOpin Rheumatol 2013;25(2):248-253.
245. Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010;19(9):1012-1019.
246. Sozzani S, BosisioD, ScarsiM, Tincani A. Type I interferons in systemic autoimmunity. Autoimmunity 2010;43(3):196-203.
247. Brkic Z,Maria NI, vanHelden-MeeuwsenCG, et al. Prevalence of interferon type I signature inCD14 monocytes of patientswith Sjogren's syndromeand associationwith disease activity and BAFF gene expression. Ann Rheum Dis. 2013;72(5):728-735.
248. Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294(5546):1540-1543. (Pubitemid 33063928)
249. Joo H, Coquery C, Xue Y, et al. Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation. J ExpMed 2012;209(7):1335-1348.
250. Teichmann LL, Ols ML, Kashgarian M, et al. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 2010;33(6):967-978.
251. Di Paolo JA, Huang T, Balazs M, et al. Specific Btk inhibition suppresses B cell-and myeloid cellmediated arthritis. Nat Chem Biol 2011;7(1):41-50.
252. Taylor KE,Chung SA,GrahamRR, et al.Risk alleles for systemic lupus erythematosus in a large casecontrol collection and associations with clinical subphenotypes. PLos Genet 2011;7(2):e1001311.